| scholarly article | Q13442814 |
| P356 | DOI | 10.4137/CGM.S21221 |
| P8608 | Fatcat ID | release_wlnqoaxvwzdyrm735mfif5eojq |
| P3181 | OpenCitations bibliographic resource ID | 1959241 |
| P932 | PMC publication ID | 4558890 |
| P698 | PubMed publication ID | 26380555 |
| P2093 | author name string | Karen D Cowden Dahl | |
| Alexander S Bobbs | |||
| Jennifer M Cole | |||
| P2860 | cites work | Identification and characterization of ovarian cancer-initiating cells from primary human tumors | Q24644329 |
| Patient-derived xenograft models to improve targeted therapy in epithelial ovarian cancer treatment | Q26829125 | ||
| Recent concepts of ovarian carcinogenesis: type I and type II | Q27009487 | ||
| Integrated genomic analyses of ovarian carcinoma | Q27860518 | ||
| Ovarian surface epithelium: biology, endocrinology, and pathology | Q28211321 | ||
| Pathway-specific engineered mouse allograft models functionally recapitulate human serous epithelial ovarian cancer | Q28538059 | ||
| Xenograft of microencapsulated Sertoli cells for the cell therapy of type 2 diabetes mellitus in spontaneously diabetic nonhuman primates: preliminary data. | Q30843239 | ||
| TP53 mutations in human cancers: origins, consequences, and clinical use | Q33685392 | ||
| MUC1 positive, Kras and Pten driven mouse gynecologic tumors replicate human tumors and vary in survival and nuclear grade based on anatomical location | Q33981906 | ||
| Humanized Mouse Model of Ovarian Cancer Recapitulates Patient Solid Tumor Progression, Ascites Formation, and Metastasis | Q34026088 | ||
| Ovulation and extra-ovarian origin of ovarian cancer | Q34063581 | ||
| Ovarian cancer development and metastasis | Q34086819 | ||
| A genetically engineered ovarian cancer mouse model based on fallopian tube transformation mimics human high-grade serous carcinoma development. | Q34111959 | ||
| Epigenetic targeting of ovarian cancer stem cells | Q34135466 | ||
| Endometriosis: candidate genes. | Q34158341 | ||
| Role of T antigen interactions with p53 in tumorigenesis | Q34177970 | ||
| Transformation of the fallopian tube secretory epithelium leads to high-grade serous ovarian cancer in Brca;Tp53;Pten models | Q34391423 | ||
| Ovarian cancer stem cells express ROR1, which can be targeted for anti-cancer-stem-cell therapy | Q34448718 | ||
| Ovarian carcinogenesis: an alternative hypothesis. | Q34785955 | ||
| Anoikis resistance is a critical feature of highly aggressive ovarian cancer cells | Q35097243 | ||
| Molecular correlates of platinum response in human high-grade serous ovarian cancer patient-derived xenografts | Q35448716 | ||
| Preclinical testing of PI3K/AKT/mTOR signaling inhibitors in a mouse model of ovarian endometrioid adenocarcinoma. | Q35589601 | ||
| A mouse model for the molecular characterization of brca1-associated ovarian carcinoma | Q35646878 | ||
| Human tumour xenografts established and serially transplanted in mice immunologically deprived by thymectomy, cytosine arabinoside and whole-body irradiation | Q36043673 | ||
| Perturbation of Rb, p53, and Brca1 or Brca2 cooperate in inducing metastatic serous epithelial ovarian cancer | Q36170279 | ||
| Induction of ovarian cancer by defined multiple genetic changes in a mouse model system | Q36496578 | ||
| Adaptor plasmids simplify the insertion of foreign DNA into helper-independent retroviral vectors | Q36919124 | ||
| New hypothesis on pathogenesis of ovarian cancer lead to future tailored approaches. | Q37155964 | ||
| Getting to know ovarian cancer ascites: opportunities for targeted therapy-based translational research | Q37196532 | ||
| Histopathology of ovarian tumors in laying hens: a preclinical model of human ovarian cancer. | Q37381736 | ||
| Immunobiology of human mucin 1 in a preclinical ovarian tumor model | Q37527861 | ||
| Tumorgrafts as in vivo surrogates for women with ovarian cancer. | Q37626455 | ||
| A new spontaneously transformed syngeneic model of high-grade serous ovarian cancer with a tumor-initiating cell population. | Q37642705 | ||
| Development of a mouse model of menopausal ovarian cancer | Q38195046 | ||
| Peritoneal mesothelium promotes the progression of ovarian cancer cells in vitro and in a mice xenograft model in vivo. | Q38949227 | ||
| Müllerian inhibiting substance type II receptor (MISIIR): a novel, tissue-specific target expressed by gynecologic cancers. | Q40055296 | ||
| Characterization of intraperitoneal, orthotopic, and metastatic xenograft models of human ovarian cancer | Q40488126 | ||
| Recombinant CD40 ligand therapy has significant antitumor effects on CD40-positive ovarian tumor xenografts grown in SCID mice and demonstrates an augmented effect with cisplatin. | Q40774013 | ||
| Development of a syngeneic mouse model for events related to ovarian cancer | Q40888613 | ||
| The prognostic implication of ascites in advanced-stage ovarian cancer | Q40984622 | ||
| Enhanced c-erbB-2/neu expression in human ovarian cancer cells correlates with more severe malignancy that can be suppressed by E1A. | Q41573546 | ||
| Activation of cancer-specific gene expression by the survivin promoter | Q42816919 | ||
| Establishment and characterization of cancer cell cultures and xenografts derived from primary or metastatic Mullerian cancers. | Q44308450 | ||
| Role of K-ras and Pten in the development of mouse models of endometriosis and endometrioid ovarian cancer | Q45201949 | ||
| Female mice chimeric for expression of the simian virus 40 TAg under control of the MISIIR promoter develop epithelial ovarian cancer. | Q45728676 | ||
| Improved survival in women with BRCA-associated ovarian carcinoma | Q46693199 | ||
| Induction of carcinogenesis by concurrent inactivation of p53 and Rb1 in the mouse ovarian surface epithelium. | Q53378102 | ||
| Mouse model of human ovarian endometrioid adenocarcinoma based on somatic defects in the Wnt/beta-catenin and PI3K/Pten signaling pathways. | Q54443542 | ||
| The genesis and evolution of high-grade serous ovarian cancer | Q55053523 | ||
| Lysophosphatidic acid downregulates tissue inhibitor of metalloproteinases, which are negatively involved in lysophosphatidic acid-induced cell invasion | Q58665639 | ||
| Flt-3 ligand inhibits growth of human ovarian tumors engrafted in severe combined immunodeficient mice | Q73834120 | ||
| Effects of IL-12 on human ovarian tumors engrafted into SCID mice | Q74447096 | ||
| P433 | issue | Suppl 1 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | ovarian cancer | Q172341 |
| P304 | page(s) | 29-36 | |
| P577 | publication date | 2015-01-01 | |
| P1433 | published in | Cancer growth and metastasis | Q27722549 |
| P1476 | title | Emerging and Evolving Ovarian Cancer Animal Models | |
| P478 | volume | 8 |
| Q59128081 | A Syngeneic Mouse Model of Epithelial Ovarian Cancer Port Site Metastases |
| Q89475216 | A dog oviduct-on-a-chip model of serous tubal intraepithelial carcinoma |
| Q37558633 | A patient-derived-xenograft platform to study BRCA-deficient ovarian cancers |
| Q36365016 | ANIMAL MODELS OF CANCER BIOLOGY. |
| Q90274720 | Biodistribution of Filamentous Plant Virus Nanoparticles: Pepino Mosaic Virus versus Potato Virus X |
| Q90193380 | Characteristics of in Vivo Model Systems for Ovarian Cancer Studies |
| Q26749280 | Clear cell carcinoma of the ovary: molecular insights and future therapeutic perspectives |
| Q48569329 | Comparison of Clinical Features and Outcomes in Epithelial Ovarian Cancer according to Tumorigenicity in Patient-Derived Xenograft Models. |
| Q57172159 | MUC16 as a novel target for cancer therapy |
| Q92542644 | Marine Collagen Substrates for 2D and 3D Ovarian Cancer Cell Systems |
| Q89520914 | MicroRNA targeting energy metabolism in ovarian cancer: a potent contender for future therapeutics |
| Q36159383 | NF-κB-Mediated CCL20 Reigns Dominantly in CXCR2-Driven Ovarian Cancer Progression |
| Q47553013 | The latest animal models of ovarian cancer for novel drug discovery |
Search more.